U.S. researchers found that AlloMap, a blood test from XDx, was as effective as biopsies in detecting symptoms of organ rejection and other complications in heart transplant patients. They said the blood test, which looks for an overexpression of genes linked to rejection, may spare patients from invasive and costly biopsy procedures.

Full Story:

Related Summaries